All In Biotech

NDA 018523 · Baxter Hlthcare

Acetic Acid 0.25% In Plastic Container

Acetic Acid, Glacial · Irrigation, Urethral

Last checked: Nov 20, 2026Latest source record: Sep 26, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Feb 19, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

210

41 Phase 3, 18 recruiting

FAERS reports

359

283 serious, 28 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 2, 2018.

INDICATIONS AND USAGE 0.25% Acetic Acid Irrigation, USP, is indicated as a constant or intermittent bladder rinse to help prevent the growth and proliferation of susceptible urinary pathogens (especially ammonia forming bacteria) in the management of patients who require prolonged placement of an indwelling urethral catheter. It also may be used for periodic irrigation of an indwelling catheter to help maintain patency by reducing the formation of calcium encrustations.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 19, 1982 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • ACETIC ACID 0.25% IN PLASTIC CONTAINER · ACETIC ACID, GLACIAL 250MG/100ML · SOLUTION, IRRIGATION, URETHRAL · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Acetic Acid" as an intervention, any sponsor and status, largest first.

All 210 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea41
  • diarrhoea33
  • toxicity to various agents33
  • cough27
  • dyspnoea25
  • pain24
  • coronary artery disease22
  • drug ineffective21
  • off label use21
  • arthralgia20
  • nasopharyngitis20
  • cardiac disorder19

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20054
20065
20072
20083
20093
20102
20118
20129
20137
201411
201511
201622
201713
201837
201931
202015
202124
202238
202341
202425
202517
202629

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 822 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.